← All countries · South-East Asia
99%
MCV1
2025 · WHO/UNICEF estimate
99%
DTP3
2025 · WHO/UNICEF estimate
99%
HepB3
2025 · WHO/UNICEF estimate
0
Measles cases
2025 reported
12
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 99%2025 · WHO/UNICEF estimate | 101% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 99%2025 · WHO/UNICEF estimate | 99.6% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 99%2025 · WHO/UNICEF estimate | 101.8% | B · good | |
| IPV1First dose of inactivated polio vaccine | 99%2025 · WHO/UNICEF estimate | 102.0% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | —% · Administrative (country-reported) | — | too few points | no data |
| MCV1First dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 99.7% | B · good | |
| MCV2Second dose of measles-containing vaccine | 99%2025 · WHO/UNICEF estimate | 99.7% | B · good | |
| RCV1First dose of rubella-containing vaccine | 99%2025 · WHO/UNICEF estimate | 99.7% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 99%2025 · WHO/UNICEF estimate | 101.8% | B · good | |
| HepB birthHepatitis B birth dose within 24 hours | 99%2025 · WHO/UNICEF estimate | 100% | B · good | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 99%2025 · WHO/UNICEF estimate | 101.8% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 88.5%2025 · Administrative (country-reported) | 88.5% | too few points | D · poor |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 2%2025 · WHO/UNICEF estimate | 29.0% | too few points | D · poor |
| RotaCRotavirus vaccine, complete series | 1%2025 · WHO/UNICEF estimate | 10.1% | too few points | C · weak |
| Yellow feverYellow fever vaccine (countries at risk) | 100%2012 · Administrative (country-reported) | 100% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 99%2024 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 84%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 84%2025 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 122025 | 22.7per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Invasive meningococcal disease all countries · vaccine evidence | 12025 | 1.9per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 352025 | 66.1per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (56 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | B | General/routine | All infants |
| COVID19COVID-19 vaccine | 1 | Adults | All older persons | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Older adults with chronic conditions, adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | M4 | Risk group(s) | Given as an alternate dose for those children who had severe anaphylaxis after the 1st dose of Pentavalent vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M6 | Risk group(s) | Given as an alternate dose for those children who had severe anaphylaxis after the 1st dose of Pentavalent vaccine |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | Y4 | Risk group(s) | Given as an alternate dose for those children who had severe anaphylaxis after the 1st dose of Pentavalent vaccine |
| DTWPDTwP (Whole cell) vaccine | 4 | Y4 | General/routine | All children aged 4 years |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | All infants |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | All infants |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | All infants |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | All newborns |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | M4 | Risk group(s) | Given as an alternate dose for those children who had sever anaphylaxis after the 1st dose of Pentavalent vaccine |
| HIBHib (Haemophilus influenzae type B) vaccine | 2 | M6 | Risk group(s) | Given as an alternate dose for those children who had sever anaphylaxis after the 1st dose of Pentavalent vaccine |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y10 | HPV for females only | Females aged 10 years |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | M6 | General/routine | 6m |
| MEN_ACYW_135PSMeningococcal ACYW polysaccharide vaccine | 1 | >Y2 | Travellers | All travellers to Haj and Umrah and as per country travel requirements |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | M18 | General/routine | All children aged 18 months; MR is given as MCV1 at 9 months of age and MMR is given as MCV2 at 18 months of age |
| MRMR (Measles and rubella) vaccine | 1 | M9 | General/routine | All infants; MR is given as MCV1 at 9 months of age and MMR is given as MCV2 at 18 months of age |
| OPVOPV (Oral polio vaccine) | 1 | M2 | General/routine | All infants |
| OPVOPV (Oral polio vaccine) | 1 | >M9 | Travellers | 1. For pilgrims travelling to Haj and Umrah and 2. Travellers to Polio endemic countries |
| OPVOPV (Oral polio vaccine) | 2 | M4 | General/routine | All infants |
| OPVOPV (Oral polio vaccine) | 3 | M6 | General/routine | All infants |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M2 | General/routine | All infants |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | All infants |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M6 | General/routine | All infants |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | All infants |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M4 | General/routine | All infants |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M6 | General/routine | All infants |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Adults | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >Y15 | General/routine | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | 1st contact | Pregnant women | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Adults | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | General/routine | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M1 | Pregnant women | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Adults | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | General/routine | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | Pregnant women | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Adults | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | General/routine | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | +Y1 | Pregnant women | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y15 | Adults | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | General/routine | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 5 | +Y1 | Pregnant women | >Y15 CBAW; Five doses of Td vaccine gets completed during childhood and Childbearing age. However, if these doses are not completed by the time of pregnancy, then Td vaccine is administered to pregnant women as well. |
| VITAMINAVitamin A supplements | 1 | M9 | General/routine | Every 6 months till 5 years aged to all children |
| VITAMINAVitamin A supplements | 2 | M18 | General/routine | Every 6 months till 5 years aged to all children |
| VITAMINAVitamin A supplements | 3 | M24 | General/routine | Every 6 months till 5 years aged to all children |
| VITAMINAVitamin A supplements | 4 | M30 | General/routine | Every 6 months till 5 years aged to all children |
| VITAMINAVitamin A supplements | 5 | M36 | General/routine | Every 6 months till 5 years aged to all children |
| VITAMINAVitamin A supplements | 6 | M42 | General/routine | Every 6 months till 5 years aged to all children |
| YFYF (Yellow fever) vaccine | 1 | >M9 | Travellers | All travellers to endemic countries |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.